Education
About Us
Working with TipRanks
Follow Us
Delcath Systems (DCTH)
NASDAQ:DCTH
Earnings Data
Report Date
May 12, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.08Last Year’s EPS
0.03Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents a predominantly positive operational and financial trajectory: strong volume growth (>40%), record full-year revenue, full-year profitability and materially improved adjusted EBITDA, a healthy cash position and no debt. These positives are balanced against meaningful near-term challenges — notably substantial planned increases in R&D and SG&A spending, quarter-level adjusted EBITDA softness, seasonality and site-capacity variability, and uncertainty around the 340B pricing mix and clinical trial timelines. The company positions CHOPIN publication and expanded commercial/medical field teams as key catalysts expected to accelerate adoption in the back half of 2026, but timing and execution risks remain.Company Guidance
Strong Volume and Record Revenue
Over 40% procedure volume growth in 2025 and record full-year revenue of $85,200,000 (Hepzato $78.8M, ChemoSAT $6.4M). Q4 Hepzato revenue was $19.0M vs $13.7M prior-year quarter (+~39%).
Profitability and Cash Position
Full-year 2025 net income of $2.7M (compared to a $26.4M loss in 2024) and positive full-year adjusted EBITDA of $25.1M (vs an adjusted EBITDA loss of $2.5M in 2024). Ended year with ~$91M in cash and investments, no debt, no outstanding warrants, and positive operating cash flow (Q4 operating cash flow $8.3M; full-year $22.5M).
Commercial Footprint Expansion
Operating 28 active REMS-certified treatment centers and targeting 40 active treatment centers by 2026. Early-2026 new patient starts per site per month ~0.75 (vs full-year 2025 average 0.5), and average treatments per patient remains ~4 cycles.
Encouraging Clinical Data Catalyst (CHOPIN)
CHOPIN investigator-initiated Phase 2 data reportedly show statistically significant and clinically meaningful improvements in 1-year PFS, OS and ORR when sequencing Hepzato with ipilimumab/nivolumab versus PHP alone; publication expected imminently and cited as a key commercial and guideline-influence catalyst.
Strong Gross Margins and ASP Guidance
Reported gross margins of 85% in Q4 and 86% for the full year. 2026 guidance projects gross margins between 84%–87% and an expected average selling price of around $175,000 per Hepzato kit (approx. 10% discount to published list price).
Clinical Development Progress
mCRC trial: on track to activate nearly all targeted ~26 sites by mid-2026 with interim data targeted for late 2027. mBC program targeting activation of ~15 sites by late 2026. Company evaluating additional combination immune checkpoint inhibitor trials (build plans in 3–6 months).
Capital Allocation Actions
Repurchased 628,572 common shares for $6.0M under an approved $25M buyback program, demonstrating shareholder-return activity alongside investment in growth.
DCTH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DCTH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 26, 2026 | $10.21 | $9.00 | -11.85% |
Nov 04, 2025 | $9.52 | $9.08 | -4.62% |
Aug 06, 2025 | $10.52 | $10.64 | +1.14% |
May 08, 2025 | $11.61 | $14.36 | +23.69% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Delcath Systems (DCTH) report earnings?
Delcath Systems (DCTH) is schdueled to report earning on May 12, 2026, TBA (Confirmed).
What is Delcath Systems (DCTH) earnings time?
Delcath Systems (DCTH) earnings time is at May 12, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DCTH EPS forecast?
DCTH EPS forecast for the fiscal quarter 2026 (Q1) is -0.08.